This mouse study tested whether combining an allergen-encoded mRNA–lipid nanoparticle (mRNA-LNP) vaccine with an mTOR inhibitor (rapamycin class) enhances regulatory T-cell (Treg) responses compared to mRNA-LNP alone, using a preclinical allergic asthma model.
mRNA-LNP alone drove Th1 and cytotoxic CD8+ T-cell responses that counterbalanced Th2 immunity; adding an mTOR inhibitor shifted the profile toward functional Tregs, reduced IFNγ and CD8+ responses, lowered eosinophil activation markers, and limited vaccine-associated cytotoxicity — while preserving anti-allergic efficacy.
Findings are preclinical (mouse model only); no human safety or efficacy data; the specific mTOR inhibitor used and exact dosing regimen are not detailed in the abstract.
While not yet ready for clinical use, this strategy suggests that pairing allergen-encoded mRNA-LNP vaccines with mTOR inhibition could promote durable regulatory immunity in allergy — a meaningful step beyond current immunotherapy approaches that incompletely induce Treg responses.
